Bioxytran, Inc. (BIXT)

Market Cap	4.84M -36.3%
Revenue (ttm)	n/a
Net Income	-2.35M
EPS	-0.03
Shares Out	113.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	285,838
Average Volume	234,276
Open	0.0428
Previous Close	0.0428
Day's Range	0.0400 - 0.0450
52-Week Range	0.0342 - 0.2283
Beta	2.33
RSI	42.85
Earnings Date	Mar 27, 2026

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIXT